Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Advanced Diffusion Imaging in Renal Cancer Patients

NCT: NCT06116253 · ACTIVE_NOT_RECRUITING

NCT IDNCT06116253
StatusACTIVE_NOT_RECRUITING
Start Date2022-12-01
Completion2028-12-01

Brief Summary

The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.

Frequently Asked Questions

What is Advanced Diffusion Imaging in Renal Cancer Patients?

Advanced Diffusion Imaging in Renal Cancer Patients is a clinical trial registered under NCT06116253. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06116253?

The current status of NCT06116253 (Advanced Diffusion Imaging in Renal Cancer Patients) is: ACTIVE_NOT_RECRUITING.

When did Advanced Diffusion Imaging in Renal Cancer Patients start?

Advanced Diffusion Imaging in Renal Cancer Patients started on 2022-12-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑